Curriculum Vitae
Yasco Aracava, Ph.D.
Research Associate, Department of Epidemiology and Public Health
University of Maryland School of Medicine
Date June 1st, 2017
Contact Information
Business Address: Department of Epidemiology and Public Health
10 South Pine St.
Baltimore, MD 21210
Business Phone Number: (410) 706-3563
Fax: (410) 706-4200
Email:
Foreign languages: Portuguese, Spanish
Education
1971 B.S. Pharmacy and Biochemistry, University of São Paulo, Brazil
1979 Ph.D. Physiology, University of São Paulo, Thesis Advisor –
Shirley Schreier. “Studies on the antibiotic amphotericin B on membrane permeability through the spin label method”.
Post-Graduate Education, Training and Work Experience
1982-1986 Post-doctoral Fellow, Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine
2002-2010 Post-doctoral Fellow, Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine
2010-2014 Post-doctoral Fellow, Dept. of Epidemiology and Public Health, Div. of Translational Toxicology, University of Maryland School of Medicine.
Employment History
Academic Appointments
1972-1975 Instructor, Pharmacology, Fundação Lusíadas Medical School, Brazil.
1972-1976 Instructor, Pharmacology, Fundação ABC Medical School, Brazil.
1976-1979 Instructor, Pharmacology, University of São Paulo, Brazil.
1979-1987 Assistant Professor, Pharmacology, University of São Paulo, Brazil (1982-1987 on leave of absence for post-doctoral training).
1987-1996 Adjunct Professor, Physiology, Federal University of Rio de Janeiro, Brazil.
1989-2002 Part-time position as Research Assistant Professor, in volunteer capacity, in the Department of Pharmacology & Experimental Therapeutics at UMSOM, and as Co-Director of the International Pharmacology Training Program between the UMSOM Department of Pharmacology & Experimental Therapeutics and the Laboratório de Farmacologia Molecular II, Instituto de Biofísica “Carlos Chagas Filho” in the Universidade Federal do Rio de Janeiro.
1996-2002 Associate Professor, Pharmacology, Federal University of Rio de Janeiro, Brazil
2012-present
Present Research Associate at Dept. of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine.
Professional Society Membership
1972-1982 Brazilian Society of Biophysics
1988-2002 Brazilian Society of Pharmacology and Experimental Therapeutics
1985-present Society for Neuroscience, USA
Graduate Student Teaching
1976-1982 Pharmacology to medical, pharmacy, dental and nursing schools students at University of São Paulo, Brazil.
1987-1996 Physiology do medical, pharmacy, dental and nursing schools students at Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Brazil.
1996-2002 Pharmacology to Medical, pharmacy, dental schools students at Department of Pharmacology & Experimental Therapeutics, Federal University of Rio de Janeiro, Brazil.
1988-2002 Mentor, M.Sc. (6) and Ph.D. (3) students at Federal University of Rio de Janeiro.
01/24/2017 Practical demonstration in electrophysiological recordings: U-tube drug delivery system to Graduate students of the course “Molecular Basis of Synaptic Physiology and Pharmacology” of GPILS.
Graduate Student Thesis Committee:
09/23/2016 Eric Lumsden thesis proposal committee, Toxicology Program of Graduate Program in Life Sciences (GPILS) of University of School of Medicine Part of the work was presented in ToxExpo Toxicology Society Annual meeting held on 03/12-16, 2017 with the title “Sub-acute prenatal exposure to the organophosphorus pesticide malathion causes sex-specific spatial memory deficits”.
Research collaboration:
1. GLP (Good Laboratory Practice) study “Effectiveness and safety of orally administered galantamine against acute toxicity of soman in male guinea pigs” (PI: Edson X Albuquerque).
2. Study in Cynomolgus monkeys “Pharmacokinetics and efficacy studies in non-human primates” (PI: Edson X Albuquerque)
3. Electrophysiological patch-clamp recordings in the project “Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment (PI: Todd Gould),
Publications
Peer-reviewed journal articles
1. Aracava Y, Schreier S, Phadke R, Deslauriers R, Smith IC. Spin label reduction kinetics, a procedure to study the effect of drugs on membrane permeability: the effects of monosodium urate, dimethyl sulfoxide and amphotericin B. J Biochem Biophys Methods. 1981 Aug;5(2):83-94.
2. Aracava Y, Smith IC, Schreier S. Effect of amphotericin B on membranes: a spin probe study. Biochemistry. 1981 Sep 29;20(20):5702-7.
3. Aracava Y, Schreier S, Phadke R, Deslauriers R, Smith IC. Effects of amphotericin B on membrane permeability--kinetics of spin probe reduction. Biophys Chem. 1981 Dec;14(4):325-32.
4. Ikeda SR, Aronstam RS, Daly JW, Aracava Y, Albuquerque EX. Interactions of bupivacaine with ionic channels of the nicotinic receptor. Electrophysiological and biochemical studies. Mol Pharmacol. 1984 Sep;26(2):293-30.
5. Aracava Y, Ikeda SR, Daly JW, Brookes N, Albuquerque EX. Interactions of bupivacaine with ionic channels of the nicotinic receptor. Analysis of single-channel currents. Mol Pharmacol. 1984 Sep;26(2):304-13.
6. Aracava Y, Albuquerque EX. Meproadifen enhances activation and desensitization of the acetylcholine receptor-ionic channel complex (AChR): single channel studies. FEBS Lett. 1984 Sep 3;174(2):267-74.
7. Varanda WA, Aracava Y, Sherby SM, VanMeter WG, Eldefrawi ME, Albuquerque EX. The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol Pharmacol. 1985 Aug;28(2):128-37.
8. Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol Pharmacol. 1985 Dec;28(6):527-38.
9. Albuquerque EX, Deshpande SS, Kawabuchi M, Aracava Y, Idriss M, Rickett DL, Boyne AF. Multiple actions of anticholinesterase agents on chemosensitive synapses: molecular basis for prophylaxis and treatment of organophosphate poisoning. Fundam Appl Toxicol. 1985 Dec;5(6 Pt 2):S182-203
10. Albuquerque EX, Deshpande SS, Aracava Y, Alkondon M, Daly JW. A possible involvement of cyclic AMP in the expression of desensitization of the nicotinic acetylcholine receptor. A study with forskolin and its analogs. FEBS Lett. 1986 Apr 7;199(1):113-20.
11. Rao KS, Aracava Y, Rickett DL, Albuquerque EX. Noncompetitive blockade of the nicotinic acetylcholine receptor-ion channel complex by an irreversible cholinesterase inhibitor. J Pharmacol Exp Ther. 1987 Jan;240(1):337-44.
12. Aracava Y, Deshpande SS, Rickett DL, Brossi A, Schönenberger B, Albuquerque EX. The molecular basis of anticholinesterase actions on nicotinic and glutamatergic synapses. Ann N Y Acad Sci. 1987;505:226-55
13. Aracava Y, Deshpande SS, Swanson KL, Rapoport H, Wonnacott S, Lunt G, Albuquerque EX. Nicotinic acetylcholine receptors in cultured neurons from the hippocampus and brain stem of the rat characterized by single channel recording. FEBS Lett. 1987 Sep 28;222(1):63-70.
14. Albuquerque EX, Aracava Y, Cintra WM, Brossi A, Schönenberger B, Deshpande SS. Structure-activity relationship of reversible cholinesterase inhibitors: activation, channel blockade and stereospecificity of the nicotinic acetylcholine receptor-ion channel complex. Braz J Med Biol Res. 1988;21(6):1173-96. Review.
15. Swanson KL, Aracava Y, Sardina FJ, Rapoport H, Aronstam RS, Albuquerque EX. N-methylanatoxinol isomers: derivatives of the agonist (+)-anatoxin-a block the nicotinic acetylcholine receptor ion channel. Mol Pharmacol. 1989 Feb;35(2):223-31.
16. Rozental R, Aracava Y, Scoble GT, Swanson KL, Wonnacott S, Albuquerque EX. Agonist recognition site of the peripheral acetylcholine receptor ion channel complex differentiates the enantiomers of nicotine. J Pharmacol Exp Ther. 1989 Nov;251(2):395-404.
17. Costa AC, Swanson KL, Aracava Y, Aronstam RS, Albuquerque EX. Molecular effects of dimethylanatoxin on the peripheral nicotinic acetylcholine receptor. J Pharmacol Exp Ther. 1990 Feb;252(2):507-16.
18. Kofuji P, Aracava Y, Swanson KL, Aronstam RS, Rapoport H, Albuquerque EX. Activation and blockade of the acetylcholine receptor-ion channel by the agonists (+)-anatoxin-a, the N-methyl derivative and the enantiomer. J Pharmacol Exp Ther. 1990 Feb;252(2):517-25.
19. Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther. 1990 Jul;254(1):71-82.
20. Aracava Y, Fróes-Ferrão MM, Pereira EF, Albuquerque EX. Sensitivity of N-methyl-D-aspartate (NMDA) and nicotinic acetylcholine receptors to ethanol and pyrazole. Ann N Y Acad Sci. 1991;625:451-72.
21. Albuquerque EX, Costa AC, Alkondon M, Shaw KP, Ramoa AS, Aracava Y. Functional properties of the nicotinic and glutamatergic receptors. J Recept Res. 1991;11(1-4):603-25.
22. Pereira EF, Aracava Y, Aronstam RS, Barreiro EJ, Albuquerque EX. Pyrazole, an alcohol dehydrogenase inhibitor, has dual effects on N-methyl-D-aspartate receptors of hippocampal pyramidal cells: agonist and noncompetitive antagonist. J Pharmacol Exp Ther. 1992 Apr;261(1):331-40.
23. Barbosa CT, Alkondon M, Aracava Y, Maelicke A, Albuquerque EX. Ligand-gated ion channels in acutely dissociated rat hippocampal neurons with long dendrites. Neurosci Lett. 1996 Jun 7;210(3):177-80.
24. Rocha ES, Swanson KL, Aracava Y, Goolsby JE, Maelicke A, Albuquerque EX. Paraoxon: cholinesterase-independent stimulation of transmitter release and selective block of ligand-gated ion channels in cultured hippocampal neurons. J Pharmacol Exp Ther. 1996 Sep;278(3):1175-87.
25. Marchioro M, Swanson KL, Aracava Y, Albuquerque EX. Glycine and calcium-dependent effects of lead on N-methyl-D-aspartate receptor function in rat hippocampal neurons. J Pharmacol Exp Ther. 1996 Oct;279(1):143-53.
26. Camara AL, Braga MF, Rocha ES, Santos MD, Cortes WS, Cintra WM, Aracava Y, Maelicke A, Albuguergue EX. Methamidophos: an anticholinesterase without significant effects on postsynaptic receptors or transmitter release. Neurotoxicology. 1997;18(2):589-602.
27. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997 Mar;280(3):1117-36.
28. Rocha ES, Chebabo SR, Santos MD, Aracava Y, Albuquerque EX. An analysis of low level doses of cholinesterase inhibitors in cultured neurons and hippocampal slices of rats. Drug Chem Toxicol. 1998;21 Suppl 1:191-200.
29. Castro NG, de Mello MC, de Mello FG, Aracava Y. Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393. Br J Pharmacol. 1999 Apr;126(8):1847-55.
30. Rocha ES, Santos MD, Chebabo SR, Aracava Y, Albuquerque EX. Low concentrations of the organophosphate VX affect spontaneous and evoked transmitter release from hippocampal neurons: toxicological relevance of cholinesterase-independent actions. Toxicol Appl Pharmacol. 1999 Aug 15;159(1):31-40.
31. Gonzalez-Serratos H, Chang R, Pereira EF, Castro NG, Aracava Y, Melo PA, Lima PC, Fraga CA, Barreiro EJ, Albuquerque EX. A novel thienylhydrazone, (2-thienylidene)3,4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle. J Pharmacol Exp Ther. 2001 Nov;299(2):558-66.
32. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol. 2002 May;61(5):1222-34.
33. Santos MD, Pereira EF, Aracava Y, Castro NG, Fawcett WP, Randall WR, Albuquerque EX. Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: involvement of muscarinic receptors. J Pharmacol Exp Ther. 2003 Jan;304(1):254-65.
34. Barreiro EJ, Camara CA, Verli H, Brazil-Más L, Castro NG, Cintra WM, Aracava Y, Rodrigues CR, Fraga CA. Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors. J Med Chem. 2003 Mar 27;46(7):1144-52.
35. Santos HR, Cintra WM, Aracava Y, Maciel CM, Castro NG, Albuquerque EX. Spine density and dendritic branching pattern of hippocampal CA1 pyramidal neurons in neonatal rats chronically exposed to the organophosphate paraoxon. Neurotoxicology. 2004 Mar;25(3):481-94.
36. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005 Mar;312(3):1195-205.
37. Albuquerque EX, Pereira EF, Aracava Y, Fawcett WP, Oliveira M, Randall WR, Hamilton TA, Kan RK, Romano JA Jr, Adler M. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13220-5.
38. Alkondon M, Aracava Y, Pereira EF, Albuquerque EX. A single in vivo application of cholinesterase inhibitors has neuron type-specific effects on nicotinic receptor activity in guinea pig hippocampus. J Pharmacol Exp Ther. 2009 Jan;328(1):69-82.
39. Fawcett WP, Aracava Y, Adler M, Pereira EF, Albuquerque EX. Acute toxicity of organophosphorus compounds in guinea pigs is sex- and age-dependent and cannot be solely accounted for by acetylcholinesterase inhibition. J Pharmacol Exp Ther. 2009 Feb;328(2):516-24.
40. Pereira EF, Aracava Y, Alkondon M, Akkerman M, Merchenthaler I, Albuquerque EX. Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning. J Mol Neurosci. 2010 Jan;40(1-2):196-203.
41. Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX. Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J Pharmacol Exp Ther. 2009 Dec;331(3):1014-24.
42. Gullapalli RP, Aracava Y, Zhuo J, Helal Neto E, Wang J, Makris G, Merchenthaler I, Pereira EF, Albuquerque EX. Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman. Neurotoxicology. 2010 Jan;31(1):67-76.
43. Mamczarz J, Pereira EF, Aracava Y, Adler M, Albuquerque EX. An acute exposure to a sub-lethal dose of soman triggers anxiety-related behavior in guinea pigs: interactions with acute restraint. Neurotoxicology. 2010 Jan;31(1):77-84.
44. Alexandrova EA, Aracava Y, Pereira EF, Albuquerque EX. Pretreatment of Guinea pigs with galantamine prevents immediate and delayed effects of soman on inhibitory synaptic transmission in the hippocampus. J Pharmacol Exp Ther. 2010 Sep 1; 334 (3):1051-8.
45. See comment in PubMed Commons belowPereira EF, Aracava Y, DeTolla LJ Jr, Beecham EJ, Basinger GW Jr, Wakayama EJ, Albuquerque EX. Animal models that best reproduce the clinical manifestations of human intoxication with organophosphorus compounds. J Pharmacol Exp Ther. 2014 Aug; 350(2):313-21. doi: 10.1124/jpet.114.214932. Epub 2014 Jun 6. See comment in PubMed Commons below
46. Alexandrova EA, Alkondon M, Aracava Y, Pereira EF, Albuquerque EX Galantamine prevents long-lasting suppression of excitatory synaptic transmission in CA1 pyramidal neurons of soman-challenged guinea pigs. Neurotoxicology. 2014 Sep;44:270-8. doi: 10.1016/j.neuro.2014.07.005. Epub 2014 Jul 23.
Book Chapters
1. Pereira EFR., Burt DR, Aracava Y, Kan RK, Hamilton TA, Romano Jr JA, Adler M, Albuquerque EX. Novel medical countermeasure for organophosphorus intoxication: Connection to Alzheimer’s disease and dementia, in: Chemical Warfare Agents, Chemistry, Pharmacology, Toxicology, and Therapeutics, 2nd ed. Edited by Romano Jr JA, Lukey BJ, Salem H, New York, CRC Press, 2008.
1